Leon-nanodrugs is a developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics. The companys systems support process development and GMP production of nanoparticles, engineering technology that aims to redefine precision and performance in nanoparticle production. Leon-nanodrugs empowers partners to accelerate the development of next-generation therapeutics by providing scalable, reproducible manufacturing solutions for nanoparticle-based drug delivery systems, which are critical for mRNA vaccines, gene therapies, and targeted drug delivery. Founded in 2011 and headquartered in Munich, Germany, Leon-nanodrugs has raised approximately 20.3 million at the Series D stage with investors including Evotec, BayBG Venture Capital, TVM Capital, Signet Healthcare Partners, LifeCare Partners, LBBW Venture Capital, and Albany Capital.
← All startups
Leon-nanodrugs
Series DLeon-nanodrugs is a developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics. The companys systems support process development and GMP production of nanoparticles, engineering technology that aims to redefine precision and performance in nanoparticle production. Leon-nanodrugs empowers partners to accelerate the development of next-generation therapeutics by providing scalable,…
About
Business model
Nanotechnology > Nanostructures > Diversified,
Drug Delivery > Diversified
Institutional investors
Eckenstein-Geigy-FoundationCD-VentureEvotecBayBG Venture CapitalTVM CapitalSignet Healthcare PartnersLifeCare PartnersLBBW Venture CapitalAlbany Capital
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.